Charles Schwab
ORGO icon

Charles Schwab’s Organogenesis Holdings ORGO Stock Holding History

Charles Schwab’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.09M Buy
879,832
+173,133
+24% +$600K ﹤0.01% 2708
2025
Q4 		$3.66M Sell
706,699
-155,946
-18% -$756K ﹤0.01% 2573
2025
Q3 		$3.64M Sell
862,645
-96,055
-10% -$447K ﹤0.01% 2566
2025
Q2 		$3.51M Buy
958,700
+123,654
+15% +$461K ﹤0.01% 2480
2025
Q1 		$3.61M Sell
835,046
-90,614
-10% -$366K ﹤0.01% 2410
2024
Q4 		$2.96M Sell
925,660
-22,791
-2% -$76.5K ﹤0.01% 2549
2024
Q3 		$2.71M Buy
948,451
+23,675
+3% +$66.4K ﹤0.01% 2612
2024
Q2 		$2.59M Buy
924,776
+14,037
+2% +$37.7K ﹤0.01% 2612
2024
Q1 		$2.59M Buy
910,739
+76,731
+9% +$261K ﹤0.01% 2521
2023
Q4 		$3.41M Buy
834,008
+7,516
+0.9% +$21K ﹤0.01% 2465
2023
Q3 		$2.63M Buy
826,492
+28,326
+4% +$90K ﹤0.01% 2518
2023
Q2 		$2.65M Buy
798,166
+9,013
+1% +$26.6K ﹤0.01% 2468
2023
Q1 		$1.68M Buy
789,153
+1,092
+0.1% +$2.7K ﹤0.01% 2570
2022
Q4 		$2.12M Buy
788,061
+12,998
+2% +$37.9K ﹤0.01% 2557
2022
Q3 		$2.51M Buy
775,063
+107,118
+16% +$484K ﹤0.01% 2521
2022
Q2 		$3.26M Sell
667,945
-5,417
-0.8% -$33.3K ﹤0.01% 2378
2022
Q1 		$5.13M Buy
673,362
+88,581
+15% +$686K ﹤0.01% 2265
2021
Q4 		$5.4M Sell
584,781
-34,051
-6% -$362K ﹤0.01% 2308
2021
Q3 		$8.81M Buy
618,832
+241,350
+64% +$3.75M ﹤0.01% 2083
2021
Q2 		$6.27M Buy
377,482
+731
+0.2% +$13.6K ﹤0.01% 2235
2021
Q1 		$6.87M Buy
376,751
+17,125
+5% +$232K ﹤0.01% 2145
2020
Q4 		$2.71M Buy
359,626
+193,950
+117% +$921K ﹤0.01% 2511
2020
Q3 		$637K Buy
165,676
+16,196
+11% +$64K ﹤0.01% 2814
2020
Q2 		$575K Buy
149,480
+26,386
+21% +$95.1K ﹤0.01% 2777
2020
Q1 		$398K Buy
123,094
+6,606
+6% +$28.3K ﹤0.01% 2791
2019
Q4 		$561K Buy
116,488
+57,572
+98% +$365K ﹤0.01% 2779
2019
Q3 		$388K Sell
58,916
-27,579
-32% -$153K ﹤0.01% 2898
2019
Q2 		$658K Buy
86,495
+23,180
+37% +$170K ﹤0.01% 2710
2019
Q1 		$475K Buy
+63,315
New +$1.26M ﹤0.01% 2780

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Charles Schwab's ORGO Position: Q1 2026 in Review

Charles Schwab increased its Organogenesis Holdings (ORGO) stake by 24% in Q1 2026, buying an estimated $600K and bringing the position to 879,832 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2708.

Charles Schwab first reported a position in ORGO in Q1 2019 and has held it in 29 quarters since. The position peaked at $8.81M in Q3 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • Charles Schwab held 879,832 shares of Organogenesis Holdings worth $2.09M as of Q1 2026.
  • Charles Schwab bought 173,133 Organogenesis Holdings shares in Q1 2026, an estimated $600K.
  • Organogenesis Holdings made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2708 holding.
  • Charles Schwab first reported a position in Organogenesis Holdings in Q1 2019 and has held it in 29 quarters since.
  • Charles Schwab's Organogenesis Holdings position peaked at $8.81M in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.